First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

BACKGROUND: Remogliflozin etabonate (RE) is the prodrug of remogliflozin, a selective inhibitor of the renal sodium-dependent glucose transporter 2 (SGLT2), which could increase urine glucose excretion (UGE) and lower plasma glucose in humans. METHODS: This double-blind, randomized, placebo-controll...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kapur, Anita, O’Connor-Semmes, Robin, Hussey, Elizabeth K, Dobbins, Robert L, Tao, Wenli, Hompesch, Marcus, Smith, Glenn A, Polli, Joseph W, James Jr, Charles D, Mikoshiba, Imao, Nunez, Derek J
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3700763/
https://ncbi.nlm.nih.gov/pubmed/23668634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-6511-14-26
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars